Sana Biotechnology (SANA)
(Delayed Data from NSDQ)
$5.09 USD
-0.13 (-2.49%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $5.10 +0.01 (0.20%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SANA 5.09 -0.13(-2.49%)
Will SANA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SANA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SANA
4 Stocks to Keep a Tab on for Amazing Earnings Acceleration
Are You Looking for a Top Momentum Pick? Why Sana Biotechnology (SANA) is a Great Choice
SANA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sana Bio (SANA) Stock Rallies 105% in 3 Months: Here's Why
Should IQ Chaikin U.S. Small Cap ETF (CSML) Be on Your Investing Radar?
Can Cigna's (CI) Q1 Earnings Beat on Medical Customers Growth?
Other News for SANA
Sana Biotechnology initiated with bullish view at Rodman & Renshaw
SANA Crosses Below Key Moving Average Level
Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer
Noteworthy Monday Option Activity: SANA, GLNG, GXO
GFS, PETS and CYTK are among after hour movers